Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues

作者：Ruizhi Geng, Jasmin Knoll, Niklas Harland, Bastian Amend, Markus D. Enderle, Walter Linzenbold, Tanja Abruzzese, Claudia Kalbe, Elisabeth Kemter, Eckhard Wolf, Martin Schenk, Arnulf Stenzl, Wilhelm K. Aicher · 发表于：Cell Transplantation · 年份：2022 · DOI：10.1177/09636897221080943 · 被引用次数：8 · 研究领域：Body Contouring and Surgery、Tendon Structure and Treatment、Mesenchymal stem cell research

Current regimen to treat patients suffering from stress urinary incontinence often seems not to yield satisfactory improvement or may come with severe side effects. To overcome these hurdles, preclinical studies and clinical feasibility studies explored the potential of cell therapies successfully and raised high hopes for better outcome. However, other studies were rather disappointing. We therefore developed a novel cell injection technology to deliver viable cells in the urethral sphincter complex by waterjet instead of using injection needles. We hypothesized that the risk of tissue injury and loss of cells could be reduced by a needle-free injection technology. Muscle-derived cells were obtained from young male piglets and characterized. Upon expansion and fluorescent labeling, cells were injected into cadaveric tissue samples by either waterjet or injection needle. In other experiments, labeled cells were injected by waterjet in the urethra of living pigs and incubated for up to 7 days of follow-up. The analyses documented that the cells injected by waterjet in vitro were viable and proliferated well. Upon injection in live animals, cells appeared undamaged, showed defined cellular somata with distinct nuclei, and contained intact chromosomal DNA. Most importantly, by in vivo waterjet injections, a significantly wider cell distribution was observed when compared with needle injections ( P < .05, n ≥ 12 samples). The success rates of waterjet cell application in livin...